scholarly journals Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema

2005 ◽  
Vol 89 (1) ◽  
pp. 74-80 ◽  
Author(s):  
J K Luttrull
Keyword(s):  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Clinically Significant

scholarly journals Subthreshold 577 nm laser photocoagulation vesus conventional 532 nm laser photocoagulation for diabetic macular oedema

2021 ◽  
Vol 3 (3) ◽  
pp. 123-140
Author(s):  
Linda Sui-Lin Ong ◽  
Tajunisah Mohd Iqbal ◽  
Kenneth Choong-Sian Fong
Keyword(s):  
Diode Laser ◽  
Macular Oedema ◽  
Laser Photocoagulation ◽  
Retinal Thickness ◽  
Diabetic Macular Oedema ◽  
Macular Thickness ◽  
Clinically Significant ◽  
Clinically Significant Macular Oedema ◽  
532 Nm

Purpose: To evaluate the visual and anatomic outcomes of the subthreshold micropulse 577 nm yellow diode laser (MYL) and to compare its efficacy with the conventional green 532 nm diode laser (CGL) in Asian eyes with diabetic macular oedema (DME).Study design: Prospective randomized controlled clinical trialMethods: Sixty-seven eyes of 43 patients with clinically significant macular oedema (CSME) were randomized to receive either MYL (n = 37) or CGL (n = 30) at baseline and were followed up for 12 months. Titration in the MYL group was performed with 15% duty cycle, 300 ms duration, and double the threshold power, while the modified Early Treatment of Diabetic Retinopathy Study (mETDRS) protocol was used for the CGL arm with the power titrated to a barely visible burn. Parameters noted included best-corrected visual acuity (BCVA) (logMAR), central subfoveal thickness (CST), macular volume (MV), and average macular thickness (AMT) using optical coherence tomography, and presence of visible laser scars on colour fundus photographs and fundus autofluorescence, at baseline and at 12 months.Results: At 12 months follow-up, BCVA improved by 4.7 and 8.8 letters, respectively, for the MYL and CGL treatment arms (p < 0.05). There was a significant reduction in all retinal thickness parameters (CST, MV, and AMT) when compared to baseline in both laser treatment arms at 12 months. There was no significant difference in either BCVA or retinal thickness parameters between the two treatment arms at 1, 3, 6, 9, or 12-month follow-up. Laser scars were observed in 26.7% of patients in the MYL group compared to 75% of patients in the CGL group (p = 0.029).Conclusions: MYL is an effective, safe, and patient-friendly treatment option for clinically significant macular oedema, with improvement in BCVA, reduction in macular thickness, and less scarring after treatment at 12 months.

scholarly journals Profile of a population-based diabetic macular oedema study: the Liverpool Eye and Diabetes Study (Sydney)

BMJ Open ◽  
2019 ◽  
Vol 9 (1) ◽  
pp. e021884 ◽  
Author(s):  
Gerald Liew ◽  
Vincent W Wong ◽  
Mercy Saw ◽  
Tania E Tsang ◽  
Tim Nolan ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Systemic Disease ◽  
Diabetic Macular Oedema ◽  
Population Based ◽  
Cross Sectional ◽  
Population Prevalence ◽  
Systemic Factors ◽  
Clinically Significant

PurposeThe population prevalence of diabetic macular oedema (DME) is unclear. Previous estimates have depended on photographic grading of clinically significant macular oedema, which is subjective and has resulted in widely varying estimates. With the advent of optical coherence tomography (OCT), the presence and severity of DME can now be assessed objectively and accurately.MethodsThe Liverpool Eye and Diabetes Study (LEADS) is a cross-sectional population-based study of patients with type 1 and type 2 diabetes in a multi-ethnic region of Sydney, Australia, to determine the population prevalence of OCT-defined DME, how this varies by ethnicity and association with systemic factors. This report describes the rationale, methodology and study aims.ResultsTo date 646 patients out of an expected sample size of 2000 have been recruited. Baseline data are presented for patients with type 1 (n=75, 11.8%) and type 2 (n=562, 88.2%) diabetes recruited to date. Patients with type 1 diabetes were younger (39.5vs60.7 years), with longer duration of diabetes (18.1vs11.7 years), slightly worse glycaemic control (HbA1c 9.0vs8.3), and less likely to have hypertension (30.7vs71.4%), hypercholesterolaemia (33.3vs74.6%) and obesity (31.1vs51.5%, respectively, all p<0.05).ConclusionsThe LEADS will provide objective estimates of the population prevalence of DME, how this varies with ethnicity and associations with systemic disease.

Subthreshold micropulse diode laser photocoagulation for clinically significant diabetic macular oedema: a three-year follow up

2007 ◽  
Vol 35 (7) ◽  
pp. 640-644 ◽  
Author(s):  
Sobha Sivaprasad ◽  
Ranjit Sandhu ◽  
Anamika Tandon ◽  
Khalid Sayed-Ahmed ◽  
Dominic A McHugh
Keyword(s):  
Diode Laser ◽  
Macular Oedema ◽  
Laser Photocoagulation ◽  
Diabetic Macular Oedema ◽  
Clinically Significant
Sign in / Sign up

Export Citation Format

Share Document